Nearly 500 life science innovators tuned in to our global webinar on November 14th to gain insights into the unique challenges and opportunities in rare disease R&D.   We brought together our industry’s foremost experts from Third Rock Ventures, Shire, Editas Medicine, and Genzyme to discuss the newest R&D advancements in disease understanding, diagnosis, and therapeutic intervention. The panel faculty also shared perspectives on patient engagement, clinical and regulatory pathways, pricing, and market accessibility to orphan drugs.  During the interactive discussion, the panel addressed many of the over 40 questions submitted by audience in advance or during the live session.  The life science community’s enthusiasm for the event highlighted the passion and commitment among companies large and small for helping patients affected with rare diseases with new insights, new diagnosis, and new therapies.

In case you missed the webinar, it is now available on demand by the following link below.  We welcome receiving your input and feedback in the comments area.

ON-DEMAND VIDEO LINK:  https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&eventid=879068&sessionid=1&key=5BFB6FB49BB2A658859709D64ED66569&sourcepage=register

See more information about the webinar here.

Take post webinar survey here.

 

Related articles:

WuXi Launches An Online Resource and Service Platform Dedicated to Rare Diseases
Congratulation to TaiMed Biologics on Receiving Orphan Drug Designation for Ibalizumab from FDA